Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Asparaginase
medac UK
L01XX02
Asparaginase
10000unit
Powder for solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 08010500; GTIN: 4037353016651
OBJECT 1 SPECTRILA 10,000 U POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 18-Aug-2017 | medac GmbH This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. Name of the medicinal product Spectrila 10,000 U powder for concentrate for solution for infusion 2. Qualitative and quantitative composition Each vial contains 10,000 units of asparaginase*. One unit (U) is defined as the quantity of enzyme required to liberate one µmol ammonia per minute at pH 7.3 and 37°C. After reconstitution each ml contains 2,500 units of asparaginase. *Produced in _Escherichia coli _cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for concentrate for solution for infusion. White powder. 4. Clinical particulars 4.1 Therapeutic indications Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults. 4.2 Posology and method of administration Spectrila should be prescribed and administered by physicians and health care personnel experienced in the use of antineoplastic products. It should only be given in a hospital setting where appropriate resuscitation equipment is available. Posology Spectrila is usually employed as part of combination chemotherapy protocols with other antineoplastic agents (see also section 4.5). _Adults and children older than 1 year _ The recommended intravenous dose of asparaginase is 5,000 units per square metre (U/m²) body surface area (BSA) given every third day. Treatment may be monitored based on the trough serum asparaginase activity measured three days after administration of Spectrila. If asparaginase activity values fail to reach target levels, a switch to a different Read the complete document